Voronoi, Inc. (KOSDAQ:310210)

South Korea · Delayed Price · Currency is KRW

111,000

+1,300 (1.19%)

Nov 13, 2026, 3:30 PM KST

Market Cap	2.01T -48.0%
Revenue (ttm)	4.16B +24.2%
Net Income	-69.13B
EPS	-3,806.32
Shares Out	18.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,211
Open	111,400
Previous Close	109,700
Day's Range	109,400 - 119,200
52-Week Range	90,000 - 375,500
Beta	1.63
Analysts	Buy
Price Target	340,000.00 (+206.31%)
Est. Earnings	Nov 13, 2026

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 169

Stock Exchange KOSDAQ

Ticker Symbol 310210

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 310210 stock is "Buy." The 12-month stock price target is ₩340,000, which is an increase of 206.31% from the latest price.

Price Target

₩340,000

(206.31% upside)

Analyst Consensus: Buy

Stock Forecasts